Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period ending February 23, 2023. The filing serves to furnish the Company's half-year information report for the period ended December 31, 2022, which was originally lodged with the Australian Securities Exchange (ASX).
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. Revenue, profit, cash flow, margins, debt, and liquidity figures are not present in this excerpt; they are contained within the referenced Exhibit 99.1 (ASX Half-Year Information).
Material Changes
No material changes or comparative financial analysis are detailed in this specific filing text. The document solely references the submission of the half-year report.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, or details on contingencies. These items are expected to be found in the attached half-year report (Exhibit 99.1).
Investor Verification Checklist
- Verify the correct registrant name is Bionomics Limited, not Neuphoria Therapeutics Inc.
- Review Exhibit 99.1 for the actual financial statements and operational results for the six months ended December 31, 2022.
- Confirm the filing date of February 23, 2023, aligns with the ASX lodgement date.